Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990159 | 0.91 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1MAPTALDH1A1HSP90AB1 | |
| SCHEMBL13451780 | 0.85 | PDK2 (0.45) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL11373632 | 0.85 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL10229644 | 0.83 | LMNA (0.50) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL279655 | 0.83 | ALDH1A1 (0.53) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL4249140 | 0.82 | ALDH1A1 (0.64) | SMN1; SMN2L3MBTL1MAPTALDH1A1KDM4E | |
| SCHEMBL26349859 | 0.81 | CNR1 (0.47) | SMN1; SMN2L3MBTL1MAPTALDH1A1KDM4E | |
| SCHEMBL7833654 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL7596837 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL9008317 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233639-A | Preparation method of 4,4' -dihydroxy diphenyl ether | 甘肃金盾化工有限责任公司 | 2020-06-05 | — | — | CN | claimed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240190899-A1 | ORGANIC COMPOUND, OPTO-ELECTRONIC DEVICE, ELECTRONIC APPARATUS, AND ELECTRONIC DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2024-06-13 | — | — | US | disclosed |
| CN-117939904-A | Organic compound, electro-optical device, electronic apparatus, and electronic device | 三星显示有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | HONGENE BIOTECH CORPORATION | 2023-02-02 | — | — | US | disclosed |
| CN-111233639-B | Preparation method of 4,4' -dihydroxy diphenyl ether | 甘肃金盾化工有限责任公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| US-20150187589-A1 | HARDMASK COMPOSITION AND METHOD OF FORMING PATTERNS USING THE HARDMASK COMPOSITION | SAMSUNG SDI CO., LTD. (KR) | 2015-07-02 | — | — | US | disclosed |
| WO-2015087993-A1 | OXAZOLIDINE AND OXAZINANE DERIVATIVES | 大正製薬株式会社 | 2015-06-18 | — | — | WO | disclosed |
| US-8158454-B2 | Method for manufacturing solar cell module | SANYO ELECTRIC CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| WO-2012000598-A1 | METHOD FOR THE PREPARATION OF CIS-1,2-DIOLS IN THE KILOGRAM SCALE | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-1630213-B2 | Ink-jet ink set and recording method using the same | KONICA MINOLTA MED & GRAPHIC (JP) | 2011-08-17 | — | — | EP | disclosed |
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100255631-A1 | METHOD FOR MANUFACTURING SOLAR CELL MODULE | SANYO ELECTRIC CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-1097073-C | Polymer composition and resist meterial | WAKO PURE CHEM IND LTD (JP) | 2002-12-25 | — | — | CN | disclosed |
| CN-1159459-A | Polymer composition and resist meterial | WAKO PURE CHEM IND LTD (JP) | 1997-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | SMN1; SMN2 4590/4885L3MBTL1 1119/4885MAPT 3181/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | SMN1; SMN2 2282/4885L3MBTL1 2113/4885MAPT 2667/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | SMN1; SMN2 4489/4885L3MBTL1 882/4885MAPT 3520/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | SMN1; SMN2 4590/4885L3MBTL1 1119/4885MAPT 3181/4885 |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | SMN1; SMN2 3156/4885L3MBTL1 4653/4885MAPT 4723/4885 |
| US-20240190899-A1 | ORGANIC COMPOUND, OPTO-ELECTRONIC DEVICE, ELECTRONIC APPARATUS, AND ELECTRONIC DEVICE | CYBB, CYBA, PPOX | SMN1; SMN2 4471/4885L3MBTL1 4713/4885MAPT 3553/4885 |
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | FUT6, B3GNT2, GALNT6 | SMN1; SMN2 1428/4885L3MBTL1 662/4885MAPT 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.